Elevai Labs, Inc. (ELAB) analyst actions
Rating and price-target actions on ELAB in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ELAB overview →
4 measured ELAB analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in Collaboration with Modulant Biosciences | Press release | +0.59% | -0.59% | |
| Northstrive Biosciences Announces Initiation of Phase II of Collaboration to Develop AI Powered Therapies for Obesity and Cardiometabolic Diseases | Press release | -3.26% | -4.22% | |
| PMGC Holdings Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance | Press release | -12.01% | -18.66% | |
| Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance | Press release | -2.35% | -6.47% |
Keep exploring
More ELAB: earnings → · SEC filings → · ELAB overview →